Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK and Genmab receive EU authorisation for Arzerra
GSK & GEN announced today that the EC has granted marketing authorisation for a new indication for the use of Arzerra™ (ofatumumab)...
GSK statement on UK Government-initiated review of antibiotic resistance
We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance.
GSK statement on recent media coverage related to our China business
Following media coverage this weekend, GSK has issued the following statement.
GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma
GSK and THRX announced the submission of a new drug application for asthma in patients aged 12 years and older, brand name Breo® Ellipta®.
GSK and Save the Children offer $1 million award for healthcare innovations in developing countries that reduce child deaths
GSK and Save the Children today announced the launch of their second annual $1 million Healthcare Innovation Award.
Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV
ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion.
GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL
GSK & GEN announced today that the Phase III study of ofatumumab (Arzerra™) did not meet its primary endpoint of PFS.
GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GSK announced the start of a Phase III study to evaluate effects of eltrombopag with azacitidine versus placebo in patients with MDS.
GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes
Data from four randomised phase III studies show that patients on albiglutide, continued to show blood glucose lowering at three years.
GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia
GSK announced the results from the Phase III PETIT2 study evaluating efficacy of eltrombopag vs. placebo in paediatric patients with cITP
ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1
ViiV announced they have entered into an agreement with Janssen for the development and commercialisation of Tivicay® Edurant®.
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD
GSK and THRX today announced positive results from two phase III studies.
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
GSK today announced the start of a pivotal phase III study to evaluate the effects of losmapimod in patients presenting with ACS.
GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GSK today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab.
Serious Fraud Office Investigation
GSK has today been informed by UK's SFO that it has opened a formal criminal investigation into the Group’s commercial practices.
GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan
GSK announced the submission of a regulatory application to the JMHLW for UMEC, a LAMA, administered using the Ellipta™ dry powder inhaler.
GSK and Genmab receive FDA approval for Arzerra® (ofatumumab)
GSK and Genmab announced today that CHMP of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation.
GSK announces new commitment to improve access to vaccines with 5-year price freeze for countries graduating from GAVI Alliance support
GSK announced today that it will freeze the prices of its vaccines for 5 years for countries that graduate from GAVI Alliance support.
motherapy for the treatment of relapsed or refractory diffuse large b-cell lymphoma
GSK & GEN announced that the Phase III study ORCHARRD of Arzerra™ or rituximab plus chemotherapy for DLBCL did not meet its primary endpoint
GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD
GlaxoSmithKline plc (LSE:GSK) today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.